EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinicopathological associations and prognostic significance of EZH2, H3K27me3, pRB, p53, and p16 expression in diffuse large B-cell lymphoma

Ishan Gupta, Surabhi Jain, Moien Rasheed Lone, Ajay Gogia, Chandan Krushna Das, Mehar Chand Sharma, Ashish Datt Upadhyay, Saumyaranjan Mallick

Journal of Pathology and Translational Medicine · 15.11.2026 · 60 (6) · 635-645

DOI: 10.4132/jptm.2026.09.14 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pathology and Translational Medicine, erschienen am 15.11.2026. Verfasst von Ishan Gupta und 7 weiteren Autor:innen. Beteiligte Einrichtung: All India Institute of Medical Sciences, New Delhi, India. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: All India Institute of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diffuse large B-cell lymphoma (DLBCL) is characterized by pronounced heterogeneity in its morphological and biological attributes, with emerging evidence highlighting the pivotal role of epigenomic alterations in its pathogenesis. This study aimed to investigate the relationship between EZH2 expression and cell-cycle regulatory proteins, focusing on their prognostic implications.

Methods

This retrospective study included 131 patients with nodal primary DLBCL, who were categorized according to the Hans algorithm and additional immunohistochemistry was performed for selected epigenetic (EZH2 and H3K27me3) and cell-cycle regulatory markers (phosphorylated retinoblastoma [pRB], p16 and p53). Receiver operating characteristic (ROC) curve analysis and Cox regression models were applied to assess prognostic utility. Appropriate statistical analysis was performed.

Results

EZH2 was expressed in 59.5% of cases and significantly associated with p53 (p = .003), germinal center B-cell-like (GCB) subtype (p = .031), and CD10 positivity (p = .030). pRB positivity was more frequent in the activated B-cell-like subtype (82.5% vs. 64.3%, p = .024) and was associated with MUM1 (p = .028), while p16 expression was linked to BCL6 (p = .004). ROC analyses demonstrated poor discriminatory ability for overall survival (area under the curve, 0.39 to 0.54), with no clinically actionable cutoffs identified. Stepwise Cox regression identified age >60 years (hazard ratio [HR], 2.04; p = .042) and Eastern Cooperative Oncology Group ≥ 2 (HR, 3.46; p = .001) as independent predictors of overall survival. For progression-free survival, no biomarker reached statistical significance.

Conclusions

EZH2 and related cell-cycle proteins demonstrate biological associations in DLBCL but lack robust prognostic utility when assessed by immunohistochemistry. Clinical variables showed stronger predictive value for survival, while no biomarker reached statistical significance for survival, underscoring the need for integrated molecular approaches to improve risk stratification and therapeutic targeting in DLBCL.

Schlagwörter

Stichwörter der Autor:innen

Cyclin-dependent kinase inhibitor p16Enhancer of zeste homolog 2 proteinHistonesLymphoma, large B-cell, diffuseRetinoblastoma proteinTumor suppressor protein p53

Autor:innen und Institutionen

  • All India Institute of Medical Sciences, New Delhi, India.
  • Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
  • David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Department of Medical Oncology, Dr. B.R. Ambedkar Institute Rotary Cancer Hospital (BRAIRCH), All India Institute of Medical Sciences, New Delhi, India.
  • Department of Internal Medicine, Boston Medical Center, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA, USA.
  • Clinical Research Unit, All India Institute of Medical Sciences, New Delhi, India.

Förderung

  • All India Institute of Medical Sciences

Zitieren

APA

Gupta, I., Jain, S., Lone, M. R., Gogia, A., Das, C. K., Sharma, M. C., Upadhyay, A. D., & Mallick, S. (2026). Clinicopathological associations and prognostic significance of EZH2, H3K27me3, pRB, p53, and p16 expression in diffuse large B-cell lymphoma. Journal of Pathology and Translational Medicine, 60(6), 635-645. https://doi.org/10.4132/jptm.2026.09.14

Vancouver

Gupta I, Jain S, Lone MR, Gogia A, Das CK, Sharma MC, et al. Clinicopathological associations and prognostic significance of EZH2, H3K27me3, pRB, p53, and p16 expression in diffuse large B-cell lymphoma. Journal of Pathology and Translational Medicine. 2026;60(6):635-645. doi:10.4132/jptm.2026.09.14

BibTeX
@article{Gupta2026,
  author = {Gupta, Ishan and Jain, Surabhi and Lone, Moien Rasheed and Gogia, Ajay and Das, Chandan Krushna and Sharma, Mehar Chand and Upadhyay, Ashish Datt and Mallick, Saumyaranjan},
  title = {Clinicopathological associations and prognostic significance of EZH2, H3K27me3, pRB, p53, and p16 expression in diffuse large B-cell lymphoma},
  journal = {Journal of Pathology and Translational Medicine},
  year = {2026},
  volume = {60},
  number = {6},
  pages = {635--645},
  doi = {10.4132/jptm.2026.09.14}
}
Kostenlos starten →